Pharmaceutical & Biotech
News and Insights
Teva - Allergan Deal Schedule to Close in June
Teva is on track to finish its $40.5 billion dollar buy of Allergan's generics unit. The deal has been in the works since last summer and with recent ending of the Pfizer/Allergan buyout shareholders have been nervous. Click here to view the entire article. ...
Shire to build a biologics plant in Ireland
Shire is expected to begin construction on a $400 million biologics plant in Peircetown, Ireland this summer. The plant will employ 400 individuals and is expected to be completed in 2019. Currently, Shire only has manufacturing plants in the US. Shire CEO Flemming Ornskov said, "Increasing our biologics manufacturing capability is fundamental to achieving our ambition of becoming the world's leading Biotechnology Company focused on rare diseases and other specialty conditions." Click here to view the entire article. ...
Pfizer-Allergan merger collapses
In an effort to cut its tax rate, Pfizer's CEO, Ian Read, has been on a mission to move the company overseas. The $160 billion purchase of Allergan would have relocated Pfizer's headquarters to Ireland. Everything was running smoothly until the US Treasury Department put a new tax-inversion rule in place. After this, both companies decided to terminate the agreement. Pfizer will decide by the end of the year whether it will split into two separate businesses. Click here to view the entire article. ...
Positive results for Eli Lilly
Eli Lilly and research partner Incyte released good news from its Phase III study for a treatment for rheumatoid arthritis. The arthritis pill named baricitinib showed a 20% improvement in patient symptoms after a 12 week period when matched with placebo results. Click here to view the entire article. ...
J&J and AbbVie cleared for first-line treatment
When AbbVie bought J&J partner Pharmacyclics last year, it was counting on Imbruvica's potential to treat chronic lymphocytic leukemia (CLL). On March 4th, the FDA cleared the way for first-line treatment of patients with CCL. This approval comes from the results of a multi-center open label Phase III study. This is a big step for patients who are seeking an alternative to customary chemotherapy treatment. Click here to view the entire article. ...
FDA providing $2 million in new grants
The U.S. Food and Drug Administration has announced $2 million in funding for natural history studies in rare disease. The program titled, Orphan Products Natural History Grants Program, will help to shed a light on how specific rare diseases progress in individuals over time so that knowledge can inform and support product development and approval. Research grant applications are due by October 14, 2016. All responsive applications will be reviewed by a panel of rare disease and natural history experts. The anticipated start date of funding for grantees is March 2017. Click here to view the entire article. ...
The Essence of Executive Recruiters
This is an interesting article how important an the Executive Recruiter is to your job search. Honing in on the top 4 mistakes C-level executives make when searching for a job. Please take a moment to read a recently published articled in Forbes Magazine. Read more ...
The Bandish Group | Winner | Best Pharma Recruitment Provider
RELEASE DATE: Wednesday, 17th February 2016 (0900 BST) TFG announces winners of the Recruiter Awards for Excellence, commending digitally focused companies The winners of the 2016 TFG Recruitment Awards were announced this week (on Wednesday 17th February). The awards recognised and rewarded innovative practice in the industry. This year saw the introduction of categories, which target trade and supply chain finance, as well as supporting sectors to this industry such as accounting, finance, and natural resources. The TFG Recruitment Awards recognise exceptional candidates driving the recruitment sector and bringing key talent into the import and export industry, worth around $3tn USD per year. Each category was judged by a panel of professional judges and 2016 was the biggest awards to date, choosing from over 100 companies across 6 recruitment sectors. James Sinclair, Trade Finance Global editor said: "Recruitment is changing, and organisations need to change with it. The digitalisation of recruitment processes, omnichannel focus and the production of engaging digital content for both potential candidates and firms looking to recruit are paramount – which was a key focus of all winners of the TFG Recruitment Awards for Excellence. "We are proud to nominate a few winners across our categories this ...
Pfizer settles Medicaid pricing lawsuit
After purchasing Wyeth in 2009, Pfizer inherited a lawsuit that claimed between 2001 and 2006 state Medicaid programs did not receive the same discount that nongovernment customers were receiving for the heartburn medication, Protonix. With the trial set to take place on March 7th, Pfizer has agreed to a $784 million to settlement. Pfizer's general counsel Doug Lankler stated, "The resolution of these cases reflects a desire by the company to put these cases behind us and to focus on the needs of the patients." Click here to view the entire article. ...
Here are some of the newly announced additions to company's throughout the industry. Rohan Palekar was named CEO of Avanir Pharmaceuticals. Syndax Pharmaceuticals has named Allan Shaw Chief Financial Officer. Dr. Craig Granowitz was named Chief Medical Officer at Amarin Pharmaceuticals On another note, Johnson & Johnson is cutting 3,000 jobs to save $1 billion to help its lagging medical devices business. Additionally, Nephron is laying off 250 employees in Orlando between March 18 and April 1. Click here to learn more about what these executives have to offer in their new roles. ...
1 of 3